Ectoenzyme-expressing ILC in GVHD-affected gut tissue. HPLC tandem-MS measurements of serum adenosine (µMo/L) (A) and inosine (µMol/L) (B) from healthy subjects (n = 5) and patients affected by GVHD (n = 10). (C) Representative flow cytometric analysis (left panel) of CD39 and CD73 expression on gut ILC3 from patients with GVHD, inflamed and noninflamed gut tissues from patients with Crohn’s disease. Histograms shows quantification (right panel) of ecto⁺ ILC3 from patients with GVHD, inflamed and noninflamed control gut tissue tissues from patients with Crohn’s disease. Data represent 3 to 5 independent experiments. Error bars show SEM, and horizontal bars show means. *P < .05 as determined by 1-way analysis of variance or Student t test.